Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...
Hosted on MSN1d
Moving mountains: Boulder woman's battle against multiple myeloma during Blood Cancer Awareness MonthA Boulder woman is opening up about her fight with multiple myeloma during Blood Cancer Awareness Month. She went from being ...
Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...
During a Case-Based Roundtable® event, Samer A. Al'Hadidi, MD, MS, discussed the CARTITUDE-4 trial of cilta-cel in patients with relapsed/refractory multiple myeloma in the first article of a 2-part ...
The Food and Drug Administration has approved Sarclisa as a first-line treatment for patients with multiple myeloma who are ...
Teclistamab produced “clinically meaningful” responses in patients with heavily pretreated multiple myeloma who had received prior anti-BCMA treatment, according to researchers.
Researchers sought to determine whether fixed-duration therapy would still be feasible for patients with RRMM who were treated with a bispecific antibody in clinical trials and discontinued.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback